NOTIFICATION

The following notification is being circulated in accordance with Article 10.6

|  |  |
| --- | --- |
| **1.** | **Notifying Member:** Canada  **If applicable, name of local government involved (Article 3.2 and 7.2):** |
| **2.** | **Agency responsible:** Health Canada  **Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:**  Canada's Notification Authority and Enquiry Point  Global Affairs Canada Technical Barriers and Regulations Division 111 Sussex Drive Ottawa, Ontario, K1A 0G2 Canada Tel: (343)203-4273  Fax: 613-943-0346 Email: [enquirypoint@international.gc.ca](mailto:enquirypoint@international.gc.ca) |
| **3.** | **Notified under Article 2.9.2 [****X],** **2.10.1 [****],** **5.6.2 [****],** **5.7.1 [****],** **other****:** |
| **4.** | **Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable):** Prescription status of medicinal ingredients for human and veterinary use (ICS: 11.120.01; HS: 3004.90) |
| **5.** | **Title, number of pages and language(s) of the notified document:** Notice of Consultation - Prescription Drug List (PDL): Brimonidine (1 page, available in English and French) |
| **6.** | **Description of content:** The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the listing for brimonidine or its salts, by adding a qualifier to the human and veterinary parts of the Prescription Drug List. |
| **7.** | **Objective and rationale, including the nature of urgent problems where applicable:** Protection of human and animal health or safety; Other |
| **8.** | **Relevant documents:**  Health Canada website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/consultation-brimonidine.html>  Posted: 1 September 2021 (available in English and French) |
| **9.** | **Proposed date of adoption:** To be determined after consultation period  **Proposed date of entry into force:** To be determined after consultation period |
| **10.** | **Final date for comments:** 31 October 2021 |
| **11.** | **Texts available from: National enquiry point [****X]** **or address, telephone and fax numbers and email and website addresses, if available, of other body:**  The electronic version of the regulatory text can be found at: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/consultation-brimonidine.html> (English) <https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/liste-drogues-ordonnance/avis-concernant-modifications/consultation-brimonidine.html> (French) |